USPTO serial 85907857
UNIQURE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 31, 2015
- Examiner
- LEVINE, HOWARD B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with UNIQURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Julianne Abelman
Julianne Abelman ABELMAN LAW PLLC16 Sutton Place, Suite 5BNew York, NY 10022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes] | SECTION 8 - CANCELLED | — |
| 005 | Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, [non-viral vectors,] gene therapy vectors, nucleic acid delivery vectors, [and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors] for medical purposes all for medical treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] pharmaceutical preparations and substances for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy [and cell therapy,] all for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,]inherited disorders, genetic disorders, single gene disorders [and cancers;] [clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other] pharmaceutical preparations [all] for use in nucleic acid-based therapy, gene therapy [and cell therapy] in the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers] | ACTIVE | — |
| 042 | Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry | ACTIVE | — |
| 044 | Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders,] inherited disorders, genetic disorders and single gene disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by uniQure IP B.V.
- Other trademarks owned by uniQure IP B.V.
- Other trademarks owned by UNIQURE BIOPHARMA B.V.
- Other trademarks owned by uniQure IP B.V.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named UNIQURE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 11, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 4, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 4, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 4, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 4, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 4, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 4, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 27, 2025 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jan 27, 2025 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jan 27, 2025 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jan 27, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 4, 2024 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Mar 31, 2024 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 1, 2021 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Apr 1, 2021 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Nov 10, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 17, 2020 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Mar 31, 2020 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 31, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 18, 2014 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Nov 18, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 29, 2014 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 29, 2014 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Oct 28, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 2, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 2, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 13, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 28, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 28, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 24, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 24, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 24, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 22, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 22, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 22, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 31, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 31, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 26, 2014 | ALIE | ASSIGNED TO LIE | — |
| Jan 16, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 16, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 5, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 5, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 5, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 5, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 25, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 22, 2013 | NWAP | NEW APPLICATION ENTERED | — |